Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KYMR
KYMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYMR News
Key Wall Street Rating Changes Overview
4d ago
CNBC
Kymera Therapeutics Q1 2026 Earnings Call Insights
Apr 30 2026
seekingalpha
Kymera Therapeutics Q1 Earnings Announcement Scheduled
Apr 29 2026
seekingalpha
Kymera's KT-621 Receives FDA Fast Track Designation
Apr 13 2026
NASDAQ.COM
Kymera Therapeutics' KT-621 Receives FDA Fast Track Designation
Apr 13 2026
Newsfilter
KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027
Apr 09 2026
moomoo
KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE
Apr 09 2026
moomoo
Nextech Reduces Stake in Kymera Therapeutics: Analysis
Mar 19 2026
NASDAQ.COM
Nextech Reduces Stake in Kymera Therapeutics
Mar 19 2026
Fool
Analysis of KYMR Options Trading Dynamics
Mar 03 2026
NASDAQ.COM
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Mar 02 2026
moomoo
Piper Sandler Raises Kymera Price Target to $140 on Strong Clinical Data
Feb 27 2026
Yahoo Finance
Kymera Therapeutics Highlights Q4 2025 Earnings Call
Feb 26 2026
seekingalpha
Kymera Therapeutics Set to Announce Q4 Earnings
Feb 25 2026
seekingalpha
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Fool
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Yahoo Finance
Show More News
